Clinical Trials Browser

Unknown × OTHER × Respiratory Tract Diseases × Clear all

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03402048 2020-11-04

EPIC

Phase 3 Unknown

567 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04371796 2020-05-01

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Phase 2 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT04133337 2019-10-21

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Phase 1/2 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT03389256 2018-01-03

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Phase 2 Unknown

144 enrolled

Thoracic

Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT02913365 2016-09-23

Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis

Unknown

1,000 enrolled

Thoracic

Arteriovenous Fistula, Bronchial Diseases, Bronchiectasis, Bronchitis, Hemoptysis, Hemorrhage, Lung Diseases, Lung Neoplasms, Mycobacterium Infections, Mycoses, Pathologic Processes, Pneumonia, Pulmonary Embolism, Respiratory Tract Diseases, Respiratory Tract Infections, Signs and Symptoms, Signs and Symptoms, Respiratory, Tuberculosis

Clinical Trials

ILST

EPIC

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis